Development of zona zoster during bortezomib treatment in patients with Relapsed/Refractory multiple myeloma

Turkish Journal of Hematology

Volumn 25, Issue 2, 2008, Pages 104-105

  Ifran, Ahmet ^a   Beyan, Cengiz ^a   Kaptan, Kürşat ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; EPIDURAL ANESTHESIA; FEMALE; HERPES ZOSTER; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PAIN; PATIENT CONTROLLED ANALGESIA; RELAPSE;

EID: 48649108472     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanlan R, Siegel D, Orlowski RZ, Kuter D, Umentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. NEJM 2003;348: 2609-17.
2. Jagannath S, Richardson P, Barlogie B. Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone. Proc Am S Clin Oncol 2003;22:582.
3. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esselltine DL, Schenkein DP, Anderson KC. A phase 2 study of two doses o bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
4. Slebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Ann RevCell Biol 1994;10:405-55.
5. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell 1996; 87:13-20.
6. Brown HJ, McBride WH, Zack JA, Sun R. Prostratin and borte zomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. Antivir Ther 2005;10:745-51.
7. Kroger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006;34:770-5.
8. Cuzick J, De Stavola B. Multiple myeloma-a case-control study. Br J Cancer 1988;57:516-20.
9. Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C, Neidhardt-Berard EM, Bouafia F, Coiffier B, Sales G. Infecflons following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med 1999;106:191-7.
10. Steingrimsdottir H, Gruber A, Kalin M, Bjorkholm M. Late infections after blood progenitor cell transplantation in patents with multiple myeloma. Am J Med 2001;110:329-30.
11. Curley MJ, Hussein SA, Hassoun PM. Disseminated herpes simplex virus and varicella zoster virus cointection in a patient taking thalidomide for relapsed multiple R myeloma. J Clin Microbiol 2002;40:2302-4.
12. Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, Kienast J. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005;29:587-90.
13. San Miguel J, Blade J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006;11:51-61.